The impact of cognitive impairment on survival and medication adherence among older women with breast cancer

Breast Cancer ◽  
2020 ◽  
Author(s):  
Yasser Alatawi ◽  
Richard A. Hansen ◽  
Chiahung Chou ◽  
Jingjing Qian ◽  
Vishnu Suppiramaniam ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cognitive Impairment ◽  
Medication Adherence ◽  
Older Women ◽  
The Impact

scholarly journals The impact of cognitive impairment on self‐regulatory styles in breast cancer survivors

2021 ◽  
Author(s):  
Jacqueline H. Becker ◽  
Charlotte Ezratty ◽  
Nusrat Jahan ◽  
Mita Goel ◽  
Yael Tobi Harris ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cognitive Impairment ◽  
Cancer Survivors ◽  
Breast Cancer Survivors ◽  
Regulatory Styles ◽  
The Impact

scholarly journals Elucidating Pretreatment Cognitive Impairment in Breast Cancer Patients: The Impact of Cancer-related Post-traumatic Stress

2015 ◽  
Vol 107 (7) ◽  
pp. djv099-djv099 ◽  
Author(s):  
K. Hermelink ◽  
V. Voigt ◽  
J. Kaste ◽  
F. Neufeld ◽  
R. Wuerstlein ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cognitive Impairment ◽  
Cancer Patients ◽  
Traumatic Stress ◽  
Breast Cancer Patients ◽  
Post Traumatic Stress ◽  
Post Traumatic ◽  
The Impact

scholarly journals Effects of breast cancer on chronic disease medication adherence among older women

2016 ◽  
Vol 25 (8) ◽  
pp. 898-907 ◽  
Author(s):  
Melissa L. Santorelli ◽  
Michael B. Steinberg ◽  
Kim M. Hirshfield ◽  
George G. Rhoads ◽  
Elisa V. Bandera ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Chronic Disease ◽  
Medication Adherence ◽  
Older Women

scholarly journals Cognitive impairment after cytotoxic chemotherapy

2019 ◽  
Vol 7 (1) ◽  
pp. 11-21 ◽  
Author(s):  
Petra Huehnchen ◽  
Antonia van Kampen ◽  
Wolfgang Boehmerle ◽  
Matthias Endres
Keyword(s):  
Breast Cancer ◽  
Colon Cancer ◽  
Cognitive Impairment ◽  
Cancer Patients ◽  
Cytotoxic Chemotherapy ◽  
Cytotoxic Drugs ◽  
Cytotoxic Agents ◽  
Cancer Type ◽  
Breast Cancer Patients ◽  
The Impact

Abstract Background Neurotoxicity is a frequent side effect of cytotoxic chemotherapy and affects a large number of patients. Despite the high medical need, few research efforts have addressed the impact of cytotoxic agents on cognition (ie, postchemotherapy cognitive impairment; PCCI). One unsolved question is whether individual cytotoxic drugs have differential effects on cognition. We thus examine the current state of research regarding PCCI. Neurological symptoms after targeted therapies and immunotherapies are not part of this review. Methods A literature search was conducted in the PubMed database, and 1215 articles were reviewed for predefined inclusion and exclusion criteria. Thirty articles were included in the systematic review. Results Twenty-five of the included studies report significant cognitive impairment. Of these, 21 studies investigated patients with breast cancer. Patients mainly received combinations of 5-fluorouracil, epirubicin, cyclophosphamide, doxorubicin, and taxanes (FEC/FEC-T). Five studies found no significant cognitive impairment in chemotherapy patients. Of these, 2 studies investigated patients with colon cancer receiving 5-fluorouracil and oxaliplatin (FOLFOX). Independent risk factors for PCCI were patient age, mood alterations, cognitive reserve, and the presence of apolipoprotein E e4 alleles. Conclusions There is evidence that certain chemotherapy regimens cause PCCI more frequently than others as evidenced by 21 out of 23 studies in breast cancer patients (mainly FEC-T), whereas 2 out of 3 studies with colon cancer patients (FOLFOX) did not observe significant changes. Further studies are needed defining patient cohorts by treatment protocol in addition to cancer type to elucidate the effects of individual cytotoxic drugs on cognitive functions.

scholarly journals Assessing the Impact of a Cooperative Group Trial on Breast Cancer Care in the Medicare Population

2012 ◽  
Vol 30 (14) ◽  
pp. 1601-1607 ◽  
Author(s):  
Pamela R. Soulos ◽  
James B. Yu ◽  
Kenneth B. Roberts ◽  
Ann C. Raldow ◽  
Jeph Herrin ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Life Expectancy ◽  
Older Women ◽  
Treatment Guidelines ◽  
Adjuvant Radiation ◽  
Adjusted Relative Risk ◽  
Data Set ◽  
Sample Mean ◽  
Medicare Population ◽  
The Impact

Purpose The Cancer and Leukemia Group B (CALGB) C9343 trial found that adjuvant radiation therapy (RT) provided minimal benefits for older women with breast cancer. Although treatment guidelines were changed to indicate that some women could forego RT, the impact of the C9343 results on clinical practice is unclear. Patients and Methods We used the Surveillance, Epidemiology, and End Results (SEER) –Medicare data set to assess the use of adjuvant RT in a sample of women ≥ 70 years old diagnosed with stage I breast cancer from 2001 to 2007 who fulfilled the C9343 inclusion criteria. We used log-binomial regression to estimate the relation between publication of C9343 and use of RT in the full sample and across strata of patient and health system characteristics. Results Of the 12,925 Medicare beneficiaries in our sample (mean age, 77.7 years), 76.5% received RT. Approximately 79% of women received RT before study publication compared with 75% after (adjusted relative risk of receiving RT postpublication v prepublication: 0.97; 95% CI, 0.95 to 0.98). Although use of RT was lower after the trial within all strata of age and life expectancy, the magnitude of this decrease did not differ significantly by strata. For instance, among patients with life expectancy less than 5 years, RT use decreased by 3.7%, from 44.4% prepublication to 40.7% postpublication. Among patients with life expectancy ≥ 10 years, RT use decreased by 3.0%, from 92.0% to 89.0%. Conclusion The C9343 trial had minimal impact on the use of RT among older women in the Medicare population, even among the oldest women and those with shorter life expectancies.

Differential effect of obesity on comorbidity risk in younger and older women with early breast cancer.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e13601-e13601
Author(s):  
Michael Lorentsen ◽  
Allison Mary Deal ◽  
Hyman B. Muss ◽  
Yi Tang Chen ◽  
Tucker Brenizer ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Older Women ◽  
Early Breast Cancer ◽  
Differential Effect ◽  
Retrospective Chart Review ◽  
Future Research ◽  
Obese Patients ◽  
Comorbidity Burden ◽  
The Impact

e13601 Background: Overall survival in women with early breast cancer (EBC) (Stage I-III) has made great strides over the past several decades, with survivors more likely to die from causes other than breast cancer. This study investigates the differential effect of obesity on pre-treatment comorbidity risk in younger versus older women with EBC. Methods: This is a retrospective chart review of women with EBC, age 21 and older, seen at a single institution. Differences in 18 common comorbidities were assessed by age ( > = 65 vs < 65) and Body Mass Index/BMI ( > = BMI 30 vs < 30), with relative risks (RR) estimated from log-binomial regression. Results: In a sample of 590 women, 24% were age 65+, 32% non-white, and 39% had obesity. Patients age 65+ were more likely to report 2+ comorbidities compared to age < 65 (RR 1.62, 69% v 43%). Obese patients (BMI > = 30) were more likely to report 2+ comorbidities compared to BMI < 30 (RR: 1.73, 66% v 38%). Women with obesity were more likely to have hyperlipidemia (RR: 1.85, 28% v 15%) as well as diabetes (RR: 2.51, 17% v 7%). The impact of BMI on comorbidity risk (2+ v < 2) differed by age group (interaction p < 0.001). In the < 65 group, obese patients were more likely to have 2+ comorbidities compared to non-obese (RR: 2.12, 62% v 29%, p < 0.0001). The difference was not as large in the 65+ group (RR: 1.28, 81% v 63%, p = 0.02). Conclusions: This study demonstrates increased comorbidity burden, including hyperlipidemia and diabetes, in women with obesity and EBC, especially those < 65. Providers should ensure that patients with obesity and EBC are appropriately screened and treated for underlying comorbidities. Future research should assess the impact of weight loss on overall survival in EBC patients.

Impact of cancer related stress on illness beliefs and glycemic control in breast cancer survivors with comorbid diabetes.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e24053-e24053
Author(s):  
Jenny J. Lin ◽  
Janey James ◽  
Mita Goel ◽  
Yael T Harris
Keyword(s):  
Breast Cancer ◽  
Medication Adherence ◽  
Glycemic Control ◽  
Cancer Survivors ◽  
Breast Cancer Survivors ◽  
Illness Beliefs ◽  
Event Scale ◽  
Related Stress ◽  
The Impact ◽  
The Relationship

e24053 Background: Cancer and diabetes mellitus (DM) are leading causes of death in the US and survivors with comorbid DM have a significantly higher mortality. Furthermore, posttraumatic stress disorder (PTSD) can be triggered by life-threatening illnesses such as cancer; however, little is known about the impact of cancer-related PTSD (Ca-PTSD) on illness beliefs and glycemic control. We undertook this study to assess factors associated with DM management in breast cancer survivors with DM. Methods: We recruited women with Stage 0-IIIA breast cancer diagnosed in the past 10 years, who had completed chemotherapy and/or hormonal therapy and had pre-existing DM on ≥1 oral DM medication. The Impact of Event Scale-Revised (IES-R) was used to assess distress caused by cancer. A total IES-R score of ≥33 identified those with probable Ca-PTSD. Cancer and DM related beliefs were assessed using the Illness Perception Questionnaire. Objective adherence to DM medication was assessed using electronic caps that record bottle openings. Wilcoxon rank-sum tests were used to examine the relationship between Ca-PTSD and illness beliefs. Pearson correlation tests were used to assess the relationship between cancer related stress, DM medication adherence, and glycemic control. Results: Of 111 women recruited to date, mean age was 65.4 years and 37% were black, 31% white, 14% Hispanic, 6% Asian, and 8% other. Of these, 15% had probable Ca-PTSD. Survivors with Ca-PTSD were more likely to believe the consequences of cancer and DM were more severe (median score 23.5 vs. 19.0 [p < 0.001] and 24.0 vs. 16.0 [p < 0.001], respectively), that cancer and DM were more cyclical or recurrent (15.0 vs. 9.0 [p = 0.002] and 13.0 vs. 8.5 [p = 0.002], respectively), and there was greater emotional impact due to cancer and DM (24.0 vs. 16.5 [p < 0.001] and 23.0 vs. 14.0 [p < 0.001], respectively). Additionally, those with Ca-PTSD were less likely to understand their cancer (14.0 vs. 20.0, p = 0.004). Furthermore, as cancer-related stress scores increased, glycemic control worsened (r = 0.23, p = 0.03) and DM medication adherence decreased (r = -0.23, p = 0.04). Conclusions: Breast cancer survivors with comorbid DM who have Ca-PTSD are more likely to have negative beliefs about both cancer and DM. Cancer-related stress is also associated with poorer glycemic control and DM medication adherence. Providers should be aware of the impact of cancer related stress on beliefs about comorbid illnesses and increase interventions that support cancer survivors to better manage their comorbidities.

scholarly journals The Impact of Using Different Reference Populations on Measurement of Breast Cancer-Related Cognitive Impairment Rates

2018 ◽  
Vol 33 (8) ◽  
pp. 956-963 ◽  
Author(s):  
Jonathan D Clapp ◽  
George Luta ◽  
Brent J Small ◽  
Tim A Ahles ◽  
James C Root ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cognitive Impairment ◽  
The Impact

scholarly journals The impact of eliminating age inequalities in stage at diagnosis on breast cancer survival for older women

2015 ◽  
Vol 112 (S1) ◽  
pp. S124-S128 ◽  
Author(s):  
M J Rutherford ◽  
G A Abel ◽  
D C Greenberg ◽  
P C Lambert ◽  
G Lyratzopoulos
Keyword(s):  
Breast Cancer ◽  
Older Women ◽  
Cancer Survival ◽  
Breast Cancer Survival ◽  
Stage At Diagnosis ◽  
The Impact
Sign in / Sign up

Export Citation Format

Share Document